Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs ProShares UltraShort Bloomberg Natural Gas ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while ProShares UltraShort Bloomberg Natural Gas ETF trades at $27.83. The key difference: ProShares UltraShort Bloomberg Natural Gas ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | KOLD | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $491.22 | $49.39 |
52-Week Low | $278.09 | $13.58 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
KOLD is trading at $26.96, up 4.25% with a bullish technical signal supported by moving averages. The stock faces resistance at $27-$29 while finding support at $25-$23 levels. Recent natural gas market volatility driven by weather patterns and LNG demand creates trading opportunities for this bearish natural gas ETF. The RSI at 73.40 indicates potential overbought conditions near-term.
As a tactical trading instrument, KOLD offers exposure to inverse natural gas price movements amid heightened energy market volatility. Key catalysts include weather-driven demand shifts and geopolitical developments affecting LNG exports. Risk factors include sudden natural gas price spikes and changing supply-demand dynamics that could pressure the fund's inverse positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →
